Biological Background and Function of GNPTAB

The GNPTAB gene encodes the precursor polypeptide that is proteolytically cleaved to generate the alpha (α) and beta (β) subunits of the UDP-GlcNAc:lysosomal enzyme GlcNAc-1-phosphotransferase complex. This hetero-hexameric enzyme complex (α2β2γ2) is localized in the Golgi apparatus and catalyzes the first and committed step in the synthesis of the mannose-6-phosphate (M6P) recognition marker on newly synthesized lysosomal hydrolases.

The M6P tag serves as the universal targeting signal recognized by M6P receptors (MPRs) on the trans-Golgi network membrane, enabling selective sorting and vesicular transport of acid hydrolases to the lysosomal compartment. Without this modification, lysosomal enzymes are missorted and secreted into the extracellular space rather than delivered to lysosomes, resulting in severe lysosomal dysfunction.

The α and β subunits encoded by GNPTAB constitute the catalytic core of the phosphotransferase complex, responsible for recognizing lysosomal protein substrates and transferring GlcNAc-1-phosphate from UDP-GlcNAc to mannose residues on the high-mannose N-glycans of lysosomal enzymes.

Disease Relevance: Mucolipidosis II and III

Loss-of-function mutations in GNPTAB result in two distinct lysosomal storage disorders depending on the severity of enzymatic impairment. Mucolipidosis II (ML II), historically termed I-cell disease, arises from near-complete loss of GlcNAc-1-phosphotransferase activity. Affected individuals show severe psychomotor retardation, skeletal abnormalities, coarse facial features, and typically do not survive beyond early childhood. The hallmark cellular pathology is the accumulation of inclusion bodies (I-cells) in fibroblasts, composed of undigested macromolecules that cannot be properly degraded due to the absence of lysosomal hydrolases.

Mucolipidosis III alpha/beta (ML IIIα/β) results from partial loss-of-function mutations in GNPTAB, producing a milder, slowly progressive phenotype characterized by joint stiffness, skeletal dysplasia, mild intellectual disability, and cardiac valve involvement. These patients typically survive into adulthood.

Recombinant Human GNPTAB Protein enables researchers to study enzyme kinetics, characterize disease-causing mutations, develop activity assays, and evaluate potential therapeutic interventions including enzyme replacement and gene therapy strategies targeting these disorders.

Research Applications of Recombinant Human GNPTAB Protein

Recombinant Human GNPTAB Protein (SKU: rp366663) is suitable for a range of in vitro biochemical and cell biology research applications:

• Enzyme Activity Assays: Use as a positive control or reference standard for GlcNAc-1-phosphotransferase activity measurements in Golgi-enriched fractions or cell lysates.
• Structural and Biophysical Studies: Suitable for structural characterization by techniques such as size-exclusion chromatography, dynamic light scattering, or cryo-electron microscopy to elucidate subunit architecture.
• Mutation Characterization: Enables comparison of wild-type versus disease-associated variant proteins to determine effects on folding, stability, and catalytic activity.
• Drug Discovery and Screening: Can be used in high-throughput assay development to identify small molecule modulators of phosphotransferase activity relevant to ML II/III therapy.
• Antibody Development and Validation: Serves as an antigen standard for generating or validating antibodies targeting GNPTAB for immunological assays.
• Protein–Protein Interaction Studies: Facilitates investigation of GNPTAB interactions with the γ subunit (encoded by GNPTG) and lysosomal enzyme substrates.

Handling, Storage, and Quality Considerations

To maintain the integrity and activity of Recombinant Human GNPTAB Protein, researchers should adhere to the following general best practices for recombinant protein handling:

• Storage: Store according to the conditions specified on the product datasheet. Recombinant proteins are typically stored at -80°C for long-term preservation and should be aliquoted upon first thaw to avoid repeated freeze-thaw cycles, which can degrade protein integrity and reduce activity.
• Handling: Thaw on ice and gently mix by pipetting. Avoid vortexing, which can denature the protein. Work on ice whenever possible to minimize proteolytic degradation.
• Formulation: Refer to the Certificate of Analysis (CoA) and product datasheet for specific buffer composition, concentration, and any carrier protein or glycerol content.
• Quality Control: Aladdin Scientific's recombinant proteins undergo quality control testing. Researchers should verify lot-specific purity and activity data from the provided CoA before use in critical experiments.

For precise storage conditions, formulation details, and functional validation data specific to rp366663, consult the product datasheet available on the Aladdin Scientific website.